Archived

This content is available here strictly for research, reference, and/or recordkeeping and as such it may not be fully accessible. If you work or study at University of Kentucky and would like to request an accessible version, please use the SensusAccess Document Converter.

US Patent Number

8008092

Publication Date

8-30-2011

Abstract

Provided are methods and compositions for the treatment or prevention of ocular angiogenesis and neovascularization. Administration of inhibitors of the CCR3 receptor or its ligands eotaxin (CCL11), eotaxin-2 (CCL24) or eotaxin-3 (CCL26) inhibits ocular angiogenesis.

Assignees

University of Kentucky Research Foundation, Lexington, KY (US)

Application Number

12/247,722

Filing Date

10/08/2008

Included in

Ophthalmology Commons

Share

COinS